BE THE MATCH BIOTHERAPIES® AND KIADIS PHARMA ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE PATIENT ACCESS TO HAPLOIDENTICAL STEM CELL THERAPIES

22.MAY 2019 AT 18:00:00 CET

Collaboration will sup­port Phase III clin­i­cal tri­al of cell ther­a­py prod­uct ATIR101(TM) for blood can­cers
 
MINNEAPOLIS & AMSTERDAM, May 22, 2019 – Be The Match BioTherapies®, an orga­ni­za­tion offer­ing solu­tions for com­pa­nies devel­op­ing and com­mer­cial­iz­ing cell and gene ther­a­pies, and Kiadis Pharma N.V. (“Kiadis”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny, today announced a strate­gic col­lab­o­ra­tion to sup­port clin­i­cal eval­u­a­tion of an inno­v­a­tive cell ther­a­py prod­uct with poten­tial to make hap­loiden­ti­cal hematopoi­et­ic stem cell trans­plan­ta­tions (HSCT) safer and more effec­tive for patients. 
 
Under the terms of the col­lab­o­ra­tion agree­ment, Be The Match BioTherapies will pro­vide logis­ti­cal and tech­no­log­i­cal solu­tions to sup­port Kiadis’ Phase III clin­i­cal tri­al for ATIR101, an adjunc­tive immunother­a­peu­tic designed to address key risks and lim­i­ta­tions of HSCT in the treat­ment of blood can­cers. 
 
Kiadis’ multi­na­tion­al Phase III clin­i­cal tri­al is eval­u­at­ing the safe­ty and effi­ca­cy of ATIR101 as an adjunc­tive treat­ment to HSCT from a half-matched (hap­loiden­ti­cal) fam­i­ly donor com­pared to post-trans­plant cyclophos­phamide (PTCy or “Baltimore” pro­to­col) in adult patients with blood can­cers. The Phase III study is cur­rent­ly enrolling patients in the EU, Canada, Israel and the U.S.
 
The col­lab­o­ra­tion will lever­age Be The Match BioTherapies’ indus­try-lead­ing exper­tise in cell deliv­ery logis­tics and sup­ply chain case man­age­ment, includ­ing the company’s MatchSource® end-to-end sup­ply chain man­age­ment soft­ware, to man­age the trans­port and pro­cess­ing of cel­lu­lar prod­ucts for use at Kiadis’ clin­i­cal tri­al sites in the U.S. and Canada.
 
“Kiadis’ quest to pro­vide bet­ter treat­ment out­comes for patients receiv­ing stem cell trans­plants is one we deeply share, giv­en the foun­da­tion­al role that our par­ent com­pa­ny, the National Marrow Donor Program®/Be The Match®, has played in improv­ing stem cell trans­plan­ta­tion for more than three decades,” said Chris McClain, vice pres­i­dent of Sales and New Business Development, Be The Match BioTherapies. “We look for­ward to uti­liz­ing our cell ther­a­py exper­tise to advance Kiadis’ impor­tant work.”
 
“We’re pleased to part­ner with Be The Match BioTherapies to progress our clin­i­cal inves­ti­ga­tion of ATIR101 and to expe­dite its avail­abil­i­ty to patients,” said Andrew Sandler, chief med­ical offi­cer of Kiadis Pharma. “We believe this ther­a­peu­tic approach could allow fam­i­ly mem­bers to serve as stem cell donors for those patients who would oth­er­wise not find a match­ing donor in time, ulti­mate­ly sav­ing lives.” 
 

Leave a Reply

Your email address will not be published. Required fields are marked *